Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib + Paclitaxel in Refractory Urothelial Cancer
NCT01108055Phase 2Completed
- Start
- Apr 2010
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in urothelial carcinoma (UC). Primary endpoint: Objective Tumor Response. Started Apr 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01108055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01108055.